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HIV infection has become a chronic disease for patients who have ready access to Highly Active Antiretroviral Therapy (HAART). HAART not only suppresses ongoing viral replication and decreases rates of transmission, but it slows the progression to AIDS indefinitely (1) (2) (3) . However, the cessation of therapy leads to a rapid rebound of viral replication, which can progress to AIDS even after decades of HAART.
In recent years, the nature of this viral reservoir has been under intense study. It is composed, to a large part, of latently infected quiescent CD4+ T cells (for review see (2) ). In these cells, the HIV provirus is integrated and remains transcriptionally silent in the host genome. As no HIV proteins are expressed, no cytopathic effects are observed and the virus cannot be cleared by the immune system (for review see (1, (3) (4) (5) ). Thus, efforts to deplete or eradicate the viral reservoir have focused on the reactivation of transcriptionally silent proviruses in latently infected cells (1, 5) . Once reactivated, viral gene expression should then kill infected cells directly or lead to their clearance by the immune system (6) . Concomitant intensified HAART would block the infection of new cells and thus prevent the spread of the virus.
Transcription of HIV depends critically on the Positive Transcription Elongation Factor b (P-TEFb), which is composed of the Cyclin Dependent Kinase 9 (CDK9) and cyclins T1 or 2 (CycT1 or CycT2) (7, 8) . P-TEFb phosphorylates negative elongation factors assembled on the RNA polymerase II (RNAPII) and the Transactivation Response (TAR) RNA stem loop (DRB-Sensitivity Induced Factor, DSIF, and Negative Elongation Factor, NELF), which stall transcription complexes on the 5' HIV long terminal repeat (LTR). Upon the phosphorylation of NELF-E or RD and Spt5, NELF dissociates from TAR and DSIF is converted to an elongation factor (9) . Next, PTEFb phosphorylates serines at position 2 (S2) in the heptapeptide repeats (52 x (YSPTSPS)) of the C-terminal domain (CTD) of RNAPII, which leads to the elongation and co-transcriptional processing of viral transcripts. Besides NF-kB, Bromodomain protein 4 (BRD4) and the Super-Elongation Complex (SEC), which bring P-TEFb to the RNAPII on the HIV LTR, the viral Transcriptional transactivator Tat also recruits P-TEFb to TAR (7, 8, 10) . This recruitment increases greatly HIV transcription and replication. Because TAR is so efficient at recruiting negative elongation factors, which stall RNAPII on the viral promoter, HIV transcription is extremely sensitive to levels and activity of P-TEFb.
In resting and terminally differentiated cells, levels of PTEFb are vanishingly low (11) (12) (13) . In growing cells, PTEFb exists in at least two different functional complexes. When active, small amounts of free P-TEFb are found on active chromatin in association with BRD4, SEC or specific transcription factors such as NF-kB, steroid hormone receptors, etc (7, 8, (14) (15) (16) (17) (18) (19) (20) . In these cells, most PTEFb is inactivated in a larger complex with Hexamethylene bisacetamide (HMBA)-induced proteins 1 and 2 (HEXIM1/2), noncoding 7SK snRNA, La-Related Protein 7 (LaRP7) and Methyl Phosphate Capping Enzyme (MePCE) (for review see (18) ). The equilibrium between these forms of P-TEFb (P-TEFb equilibrium) determines and reflects the state of activation, growth and proliferation of cells. Free P-TEFb is also required for the initial rounds of HIV transcription in the absence of Tat. Importantly, once Tat is made, which competes with HEXIM1 for binding to P-TEFb, both forms of P-TEFb can be utilized to sustain and maintain HIV replication (21) .
Compounds from diverse structural classes can reactivate HIV transcription from latency in cell lines and primary cells. They include differentiation agents such as HMBA, histone deacetylase (HDACis) and bromodomain and extraterminal (BET) bromodomain inhibitors as well as PKC agonists (for a non-exhaustive list see (22) (23) (24) (25) (26) ). Some of these compounds were also analyzed for their effects on P-TEFb. In this study, we found that although structurally and functionally divergent, HDACis, which can reactivate HIV also affect the P-TEFb equilibrium, i.e. release transiently free P-TEFb from the 7SK snRNP. This release could not be correlated with their effects on histone H3 or tubulin acetylation. Furthermore, we confirmed that levels of P-TEFb are vanishingly low in resting primary CD4 T cells. These cells must be activated to synthesize P-TEFb before effects of these other agonists become apparent. Our findings suggest that combinatorial approaches targeting P-TEFb will be required to reactivate HIV in infected individuals on HAART.
EXPERIMENTAL PROCEDURES
Cell lines, antibodies and plasmids.
JΔK cells and Jurkat cells were grown in RPMI containing penicillin (100 IU/ml), streptomycin (100 µg/ml), and 10% FBS at 37 °C with 5% CO 2 . NH1 and HeLa cells were grown in DMEM containing penicillin (100 IU/ml), streptomycin (100 µg/ml), and 10% FBS at 37 °C with 5% CO 2 . HIV release in the supernatant was quantified by p24 CA ELISA (Perkin Elmer). Antibodies used in this study for immunoprecipitations and western blotting were: anti-HEXIM1 (Hex; Abcam, ab25388), anti-CDK9 (Santa Cruz, sc-484), anti-CycT1 (Santa Cruz, sc-10750), antitubulin (Abcam, ab6046), anti-histone H3 (Active Motif, #39163), anti-panAc-histone H3 (Active Motif, #39139), anti-Ac-tubulin (Abcam, ab24610), anti-actin (Abcam, ab8227). SAHA (S1047), Tubastatin A (S2627) and MS-275 (S1053) was purchased from Selleck Chem and HMBA (H4663) from Sigma. Stock solutions were prepared in DMSO and water for HMBA. ST-80 was a kind gift from Prof. Manfred Jung (University of Freiburg, Germany).
RNA immunoprecipitations.
Jurkat or HeLa cells (2.5 x 10 6 ) were untreated or treated with compounds for 2 and 4 hours. The cells were lysed in buffer A (20 mM HEPES-KOH, pH 7.8, 0.1% NP-40, 0.2 mM EDTA) containing low salt (10 mM KCl, LS) on ice for 10 min. Cell lysates were centrifuged at 5000 X g for 5 minutes at 4 o C, and supernatants were collected. Supernatants were then pre-cleared with protein Asepharose beads and divided into three aliquots. Each aliquot was incubated with 1 µg of normal-rabbit IgG, α-HEXIM1, or anti-CDK9 antibodies overnight at 4 o C, and with 20 µL of protein-A sepharose beads pre-coated with BSA and yeast tRNA for additional 2 hours at 4 o C. Beads were washed 5 times with buffer A-containing medium salt (100 mM KCl, MS). RNA was then extracted by Trizol (Invitrogen) and analyzed by RT-quantitative PCR (RT-qPCR) to quantify 7SK snRNA associated with PTEFb. Data were normalized to input amounts of 7SK snRNA and calculated as values relative to the amount obtained with untreated cells (set to 1).
Differential salt extraction.
Differential salt extraction was carried out to determine fractions of free P-TEFb or 7SK snRNP according to Biglione et al., with some modifications (27) . Jurkat cells (5 x 10 5 ) were collected and washed twice with cold PBS. Cells were lysed in 80 µl low salt buffer (10 mM KCl, LS, 10 mM MgCl 2 , 10 mM HEPES-KOH pH 7.5, 1 mM EDTA, 1mM DTT, 0.5% NP40, proteinase inhibitor cocktail) and incubated on ice for 10 min. Lysates were then centrifuged at 5000 X g for 5 min, and supernatants were collected and designated as 7SK snRNP fractions. Pellets were washed once with 200 µl LS buffer and resuspended in 80 ml high salt buffer (450 mM NaCl, HS, 1.5 mM MgCl 2 , 20 mM HEPES pH7.5, 0.5 mM EDTA, 1 mM DTT, 0.5% NP40, proteinase inhibitor cocktail). Suspensions were mixed by vortexing briefly and incubated on ice for 10 min. Lysates were then centrifuged at 10000 X g for 5 min, supernatants were collected and designated as free P-TEFb fractions.
Preparation, activation, maintenance, infection and resting of primary CD4+ T cells.
Leukopheresis residues were obtained from the Blood Center of the Pacific (San Francisco, CA) and white blood cells were purified further using an OptiPrep (Sigma, #1556) density gradient. Naïve CD4+ T cells were purified from the buffy coat using the Dynabeads® Untouched™ Human CD4 T Cells kit (Invitrogen, #11346D) according to the manufacturer's protocol. CD4+ T cells were maintained for 24 hours in RPMI, 10% FBS, 30 U/ml IL-2 (Roche, # 10799068001) at 37 °C with 5% CO 2 before activation and expansion using anti-CD3/anti-CD28 Dynabeads (Invitrogen, #111.32D) for 14 days in RPMI, 10% FBS, 30 U/ml IL-2. Purity and activation level were determined by immunofluorescence for CD4, CD69 (Santa Cruz, sc-3608) and HLA-DR (Abcam, ab95830) by FACS. Activated CD4+T cells were infected by spin inoculation using a reporter virus with a deleted Env gene and a Luciferase reporter gene in the Nef ORF (pNL4.3ΔenvΔNef-Luc) produced in the presence of HIV-1 Env (pEnvHIV, plasmid kindly provided by Dr. Kotaro Shirakawa). Cells were reverted to a resting state by gradually decreasing the amount of IL-2 in the medium to 2 U/ml over the period of 21 days. Luciferase activity was measured over this period and reached a background plateau.
Transient transfection and luciferase assays.
HeLa cells, seeded in 24-well plates, were transfected with 1 µg of plasmid DNA using Xtreme-HP transfection reagent (Roche) according to the manufacturer's protocol. Similarly, Jurkat cells (2 x 10 6 ) were transfected with 2 µg of HIV.Luc reporter plasmid. Cells were grown in DMEM with 10% FBS and kept in 5% CO 2 , 37 o C for 48 hours. Transfected cells were treated with compounds and luciferase activity in cell lysate was determined using the Luciferase Assay System (Promega) according to the manufacturer's instruction after 24 hours.
Reverse transcription-quantitative PCR (RT-qPCR).
Total cellular RNA was extracted by Trizol reagent according to manufacturer's instruction and reverse transcribed with random hexamers using Super Script III Reverse Transcriptase (Invitrogen). The cDNA was quantified using Stratagene Mx3004P Real Time PCR system and SensiFast Sybr-green reagents (Bioline) with specific primers. The primer sequences used in this study were as follows: For GAPDH normalization, primers are described in (28) . For HEXIM1 mRNA quantification; HEXIM1 Forward: GACCTGGGAAGAGAAGAAAAAG HEXIM1 Reverse: GAGGAACTGCGTGGTGTTATAG. 7SK snRNA For: GAGGGCGATCTGGCTGCGACAT, 7SK snRNA Rev:ACATGGAGCGGTGAGGGAGGAA.
RESULTS

Only some HDACis reactivate the replication of an integrated HIV provirus in Jurkat cells.
Several HDACis can reactivate transcription of HIV in cell culture models of viral latency (22) (23) (24) (25) (29) (30) (31) (32) (33) (34) (35) . Among these, SAHA inhibits potently class I HDACs 1, 2, 3 and the class II HDAC6 (36) . To gain insight into which HDACs might be involved in HIV reactivation, we examined three additional HDACis with different HDAC specificities. Of these, MS-275 inhibits HDAC1, 2 & 3 (36), ST-80 has a strong preference for HDAC6 (37) and Tubastatin A (TBSA) is a highly specific HDAC6 inhibitor (38) . We determined the HIV reactivation potential of these different HDACis in JΔK cells. They are Jurkat cells, which contain a transcriptionally silent HIV provirus that lacks NF-kB sites (39) , which facilitates the study of HIV reactivation by processes that are independent of immune activation. Indeed, as described before (40), treatment of JΔK cells with increasing concentrations of SAHA leads to a dose-dependent reactivation of latent HIV (up to 25-fold) as measured by newly released viral particles in the supernatant (Fig. 1A , bars 2, 3 and 4). Like SAHA, ST-80 reactivated HIV in a dose-dependent fashion in these cells (Fig. 1A, bars 8, 9 and 10). In contrast, the inhibition of HDACs 1, 2 & 3 by MS-275 activated HIV transcription significantly less potently and inhibition of HDAC6 by TBSA had no effect in JΔK cells (Fig. 1A , bars 5, 6, 7 and 11, 12, 13). Furthermore, combinations of MS-275 and ST-80 did not have additive effects in JΔK cells (Fig. 1B) . By measuring levels of histone H3 (Class I HDACs) and tubulin (Class II HDAC) acetylation, western blotting confirmed the specificity of different HDACis (Fig.1A, lower panels) . Indeed, while SAHA induced the acetylation of histone H3 and tubulin, effects of MS-275 were mainly on histone H3 (Fig. 1A , top and middle panels, lanes 2 to 7). As expected, ST-80 and TBSA led to increased tubulin acetylation (Fig. 1A , top and middle panels, lanes 8 to 13). Together, these data indicate that the reactivation of HIV transcription by HDACis does not correlate with histone H3 or tubulin acetylation, i.e. inhibition of either class I or class II HDACs in Jurkat cells.
Similar effects are observed with the HIV.Luc plasmid target in Jurkat cells.
Episomal plasmids, which do not replicate, collect insignificant amounts of histones on their DNA (41) . Thus, we wanted to determine if the same HDACis would also activate transcription from the transiently expressed HIV.Luc plasmid target, which contains the HIV LTR linked to the luciferase reporter gene, in Jurkat cells. Indeed, as presented in Fig.1C , SAHA and ST-80, but not MS-275 and TBSA, increased its luciferase activity (4-fold) in Jurkat cells (bars 2 to 5). Importantly, this increase was independent of Tat, which amplifies effects of these HDACis (Fig. 1A) . These findings suggest that a mechanism different from histone H3 or tubulin acetylation is responsible for HIV reactivation by informative HDACis in Jurkat cells.
The release of free P-TEFb from the 7SK snRNP is observed with HDACis that reactivate HIV in Jurkat cells.
Other small molecules that reactivate HIV include HMBA and JQ1 (23, 24, 29, 30, 33, 42) . Previously, we observed that HMBA, SAHA and JQ1 also lead to the rapid release of free P-TEFb from the 7SK snRNP, which is required for the first rounds of HIV transcription. The release of free PTEFb also increases the synthesis of its inhibitor, HEXIM1 (23, 24, 43) . Thus, we examined levels of free PTEFb and HEXIM1 transcription and correlated them with HIV reactivation by different HDACis. First, we found that SAHA and ST-80 but not MS-275, increased transiently levels of free P-TEFb, which is associated with chromatin and can be released by high salt (Fig. 2A , left upper panels, high salt, also quantified in the right panel, bars corresponding to 0, 2, 4 and 6 hours after the addition of these compounds to Jurkat cells). This finding was confirmed using RNA-immunoprecipitation (IP), where complexes isolated with anti-CDK9 antibodies were subjected to RT-qPCR to quantify levels of associated 7SK snRNA. As presented in Fig. 2B, 4 hours after the addition of these compounds, we found that SAHA and ST-80, but not MS-275 or TBSA, led to the release of CDK9 (free P-TEFb) from the 7SK RNA (Fig. 2B, bars 
or TBSA increased levels of steady state HEXIM1 transcripts, which were measured 24 hours after the addition of these compounds (Fig. 2C, bars 2 to 5 ). These data reveal that HIV reactivation (in chromatin and on episomal plasmids) by HDACis can be correlated to the transient release of free P-TEFb from the 7SK snRNA and not histone H3 or tubulin acetylation in Jurkat cells.
Different HDACis reactivate the transcription of an integrated HIV LTR in HeLa cells.
To extend our observation in Jurkat cells to other commonly used cells, we analyzed HIV reactivation by the same HDACis in HeLa cells. NH1 cells carry an integrated HIV LTR linked to the luciferase reporter gene (44) . As presented in Fig. 3A , SAHA, MS-275 and ST-80, but not TBSA, increased HIV transcription in these cells (bars 2 to 10 and 11, 12, 13). Western blotting revealed that these HDACis acetylated appropriate proteins also in NH1 cells (Fig. 3A , lower panels, acetylated and total tubulin and histone H3). We conclude that in contrast to Jurkat cells, class I HDAC inhibition has greater effects on the HIV LTR in HeLa than in Jurkat cells. In contrast to JΔK cells, MS-275 and ST-80 also had synergistic effects in NH1 cells (Fig. 3B) . Again, effects of class II HDAC inhibition were divergent.
The release of free P-TEFb from the 7SK snRNP is also observed with HDACis that reactivate HIV in HeLa cells.
To determine if increased HIV transcription also correlates with the release of free P-TEFb from the 7SK snRNP in HeLa cells, we performed additional studies. As presented in Fig. 4A , SAHA, ST-80 and MS-275 but not TBSA released CDK9 (free P-TEFb) from the 7SK snRNA (Fig.  4A , RNA-IP, bars 2 to 5). This finding confirms that changes in the P-TEFb equilibrium also affect HIV transcription in HeLa cells. Previously, we observed that the activation of Hex.Luc by JQ1 parallels the release of free P-TEFb from the 7SK snRNP (23) . Indeed, the transiently expressed Hex.Luc was also activated by SAHA, ST-80 and MS-275 but not by TBSA (Fig. 4B , bars 2 to 5, luciferase activity 24 hours after the addition of these compounds). Together with increased HIV transcription, these findings reveal that HDACis that affect the P-TEFb equilibrium also reactivate HIV in transformed cell lines.
Levels of P-TEFb must be increased before HDACis can reactivate HIV in primary resting CD4+ T cells.
Primary resting CD4+ T cells have vanishingly low levels of P-TEFb (11-13). Since we correlated the ability of HDACis to activate HIV transcription with changes in the P-TEFb equilibrium, we reasoned that the absence of PTEFb could block effects of our strongest HDACi, SAHA. Indeed, this lack of P-TEFb could explain the poor reactivation potential of HDACis in primary cell models of HIV latency (45, 46) . Importantly, PKC agonists can increase levels of P-TEFb in resting cells without mitogenic effects (47) . Thus, we wanted to determine if combinations of PKC agonists and HDACis could reactivate HIV transcription in resting CD4+ T cells. First we examined if Bryostatin 1, a known PKC agonist (48, 49) , can increase levels of P-TEFb in resting CD4+ T cells, which were isolated from anonymous uninfected donors, activated and allowed to return to a resting state in limiting amounts of IL-2 over two weeks. The resting state of the cells was verified by detection of low levels of CD69 and HLA-DR by FACS (data not presented). While resting, cells were incubated with Bryostatin 1 or PHA as a positive control for 24 and 48 hours (Fig. 5A) . Western blotting for levels of CDK9 and CycT1 indicated that Bryostatin 1 increased levels of P-TEFb equivalently to PHA in these cells (Fig. 5A , upper two panels, lanes 2 to 5). When treated only with SAHA, levels of P-TEFb did not increase (Fig. 5A , upper two panels, lanes 7 and 8).
Next we examined HIV reactivation in the presence of Bryostatin 1 and SAHA in latently infected resting CD4+ T cells. To this purpose, CD4+ T cells were isolated, activated and infected with a non-replicating HIV (pNL4-3Luc). After infection, cells were allowed to return to a resting state in limiting amounts of IL-2 over the course of two weeks. At this point they were activated with Bryostatin 1 or SAHA alone or in combination. As presented in Fig. 5B , SAHA and Bryostatin 1 had small effects on HIV transcription (Fig. 5B , bars 2 to 4, 2-to 3-fold), respectively. However, when cells were treated with a combination of Bryostatin 1 and SAHA, HIV was reactivated potently (Fig. 5B , bars 5 and 6, 7-to 10-fold). We conclude that increased synthesis of P-TEFb is a prerequisite for HIV reactivation by HDACis in primary resting infected cells.
DISCUSSION
In this report, we could not correlate acetylation of histone H3 or tubulin, which reflect the inhibition of class I-and class II-specific HDACis, respectively, with HIV reactivation in Jurkat, HeLa or primary CD4+ T cells. All of these cells have been used as models of HIV latency. There were even differences in their responses to a potent class I-specific HDACi, MS-275, which had little to no effect in Jurkat cells, but potently activated HIV in HeLa cells. Since similar effects were observed on targets in chromatin and on episomal plasmids, to which little to no histones bind and on which nucleosomes do not form efficiently, we conclude that these HDACis affect another pathway for HIV reactivation. Indeed, we correlated their ability to release free P-TEFb from the 7SK snRNP with HIV reactivation in our transformed cell lines. Since primary resting cells contain insignificant levels of PTEFb, they had to be increased first with PKC agonists before effects of our most potent HDACi, SAHA, could be observed. We conclude that for HIV reactivation, HDACis must be able to release free P-TEFb from the 7SK snRNP in cells.
In this study, we used transformed cells, where the entire HIV genome was present (JΔK cells) or just the HIV LTR was linked to a reporter gene (NH1), both in chromatin. Importantly, since in JΔK cells, the HIV LTR lacks NF-kB sites, it is not activated via this transcription factor in Jurkat cells. Consequently, the recruitment of HDAC1 by p50 homodimers is not involved in its transcriptional repression (50) . Importantly, these experiments were repeated with the HIV LTR linked to a reporter gene in transient expression assays, confirming that HDACis stimulate HIV transcription independently of chromatin. Rather, HIV reactivation correlated with the release of free P-TEFb from the 7SK snRNP, which also increased the synthesis of its inhibitor, HEXIM1. Indeed, similar to the situation with NF-kB, which increases the transcription of its inhibitor, I-kB, free P-TEFb increases the synthesis of HEXIM1 (23, 51) . Thus, P-TEFb reassembles into the 7SK snRNP and the P-TEFb equilibrium is restored rapidly, thus causing cell cycle arrest, which can lead to apoptosis. Indeed, this increased synthesis of HEXIM1 might be the mechanism of action of these HDACis for their effects in leukemias, lymphomas and other human cancers.
Of interest, others and we observed little effect of HDAC inhibition in primary resting CD4+ cells (46, (52) (53) (54) . In these cells, levels of P-TEFb are vanishingly low, due to actions of specific miRNAs and NF-90 (11) (12) (13) 55) , which block the translation of CycT1 mRNA. This lack of PTEFb is thought to be critical for the establishment and maintenance of HIV latency (for review see (1,3) ). However, upon increased synthesis of P-TEFb, the ability our most potent HDACi, SAHA, to reactivate HIV was restored in these cells. T cell activation, PKC and TLR agonists can all increase the synthesis of CycT1 and CDK9 in primary resting CD4+ T cells. This finding also confirms the central role that P-TEFb plays in HIV reactivation in all cells.
Several previous studies suggested that class I HDACis and specifically those that inhibit HDAC3, rather than class II HDACis, might be optimal for HIV reactivation (56) (57) (58) . Indeed, our specific class II HDACi, TBSA had no effect in our cells. However, MS-275, also had little to no effect in Jurkat cells and other studies found conflicting results using yet other class I-specific HDACis in different cell lines (56, 57) . Thus, it is possible that the relevant targeted HDAC does not increase histone H3 or tubulin (19, 59) . Alternatively, this HDAC could affect the acetylation of histone H4, which is required for the binding of BRD4 and possibly other members of this family to chromatin (60, 61) . Thus, since BET bromodomain inhibition by JQ1, iBET and related compounds, which release BRD4 from chromatin, also leads to HIV reactivation (23, 29, 30, 33, 42) , the inhibition of effective HDACs might impact overall chromatin structure rather than specific epigenetic modifications at the HIV LTR. These changes in chromatin structure (compaction/decompaction) are expected to occur rapidly, as has been observed with JQ1 and HMBA (60, 61) . They would also change transcriptional profiles of the cell. In this scenario, HDACi-induced chromatin stresses, like those from DNA damage (UV light), arrested transcription (DRB, flavopiridol), apoptosis and BET bromodomain inhibition would then lead to the release free P-TEFb from the 7SK snRNP.
This correlation between P-TEFb and HIV reactivation contains important lessons for any future strategy to eradicate the viral reservoir from the infected host. Obviously, optimal HAART will have to be maintained during this treatment so as to minimize the spread of the virus to new cells. Minimally, the HIV anti-latency therapy (HALT) will contain agents that will increase levels of P-TEFb and others that will affect the P-TEFb equilibrium. For example, PKC agonists, such as Bryostatin 1, will be combined with the optimal HDACi, which at the moment is SAHA or Vorinostat, a drug that is approved for human use against cutaneous T cell lymphoma (62) . However, since cells do not tolerate high levels of free P-TEFb, after its disruption, the 7SK snRNP reassembles quickly due to the increased synthesis of HEXIM1. For HIV, it is important to note that once Tat is made, it competes with HEXIM1 for the binding to PTEFb. Thus, it can utilize P-TEFb from any source to sustain HIV transcription and replication even after cells have returned to their resting state. With this knowledge, frequent but sustained cycles of increased synthesis, release and reassembly of P-TEFb might indeed impact the reservoir of HIV in the infected host. 
FIGURE LEGENDS
A.
HDACis that reactivate HIV in Jurkat cells also release free P-TEFb from the 7SK snRNP as determined by differential salt extraction. Jurkat cells were incubated with HDACis (SAHA, 5 µM; ST-80, 30 µM; MS-275, 25 µM) for the indicated periods of time, and levels of chromatin-bound (free P-TEFb) and 7SK snRNPassociated (7SK snRNP) CDK9 protein were determined by western blotting. CDK9 levels were quantified for each time point using Image J R software and relative levels of active CDK9 were calculated [high salt/(high salt + low salt)]. Quantification is presented in the right panel and error bars are as in Fig.1 .
B.
The release of free P-TEFb from the 7SK snRNP was confirmed by RNA immunoprecipitation. Jurkat cells were treated with HDACis (SAHA, 5 µM; MS-275, 25 µM; ST-80, 30 µM; TBSA, 20 µM) for 4 hours and CDK9 was immunoprecipitated from cell lysates. CDK9-associated 7SK snRNA in immunoprecipitations was determined by RT-qPCR. Values are presented as relative enrichment with the DMSO control set to 1 . Error bars are as in Fig.1 .
C.
Levels of HEXIM1 transcripts rise with the release of free P-TEFb. Jurkat cells were treated with HDACis (SAHA, 5 µM; MS-275, 25 µM; ST-80, 30 µM; TBSA, 20 µM) for 6 hours and HEXIM1 mRNA were determined by RT-qPCR. Levels of HEXIM1 transcripts were normalized to those of GAPDH and are presented as fold activation over the DMSO control. Error bars are as in Fig.1 . 
